198 related articles for article (PubMed ID: 10353326)
1. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
2. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
3. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
5. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
6. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer.
Westerhuis LW; Delaere KP
Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749
[TBL] [Abstract][Full Text] [Related]
8. A variation in Bone Alkaline Phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa.
Calero JA; Muñoz MT; Argente J; Traba ML; Méndez-Dávila C; García-Moreno C; de la Piedra C
Clin Chim Acta; 1999 Jul; 285(1-2):121-9. PubMed ID: 10481928
[TBL] [Abstract][Full Text] [Related]
9. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
10. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
11. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Cooper EH; Whelan P; Purves D
Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
[TBL] [Abstract][Full Text] [Related]
13. [Studies of type I collagen related substances as bone metastatic markers of prostate carcinoma with special regard to serum carboxyterminal propeptide of type. I. Procollagen (PICP), cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and Urinary deoxypyridinoline levels].
Imai T; Honda M; Maeda S; Hosoya Y; Arai T; Sumi S; Umeda H; Yano M; Koga F; Arai K; Yoshida K
Nihon Hinyokika Gakkai Zasshi; 1998 Apr; 89(4):484-91. PubMed ID: 9597867
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients.
Fukumitsu N; Uchiyama M; Mori Y; Kishimoto K; Nakada J
Ann Nucl Med; 2003 Jun; 17(4):297-303. PubMed ID: 12932112
[TBL] [Abstract][Full Text] [Related]
15. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
[TBL] [Abstract][Full Text] [Related]
16. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
[TBL] [Abstract][Full Text] [Related]
17. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Saito S; Tachibana M; Murai M
J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
20. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
